What's the problem? [Regulatives / Guidelines]

posted by ElMaestro  – Denmark, 2017-05-17 12:07  – Posting: # 17367
Views: 16,788

Hi DM,

» It would be interesting to study the within study variation for the same compound in the same unit to understand which is the main source of variability. Although I understand the point of El Maestro about assay sensitivity, I don't think that could be pointed as a cause for a study which presented high variability when other studies reported low variability. I understand the approach to highly variable drugs, when the drug is actually highly variable per se and not due to study conduct or assay sensibility.

Then it all comes back to one of Helmut's favourite hobbies, calculation of confidence intervals for variabilities. I think the conclusion generally is that perhaps the drug is highly variable and perhaps it isn't.

if (3) 4

x=c("Foo", "Bar")
typeof(b[,1]) ##aha, integer?
b[,1]+1 ##then let me add 1

Best regards,

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,265 posts in 4,098 threads, 1,314 registered users;
online 11 (0 registered, 11 guests [including 11 identified bots]).

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

BEBAC Ing. Helmut Schütz